Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > OGD Director Greg Geba Resigns, Citing Differences in Vision

Drug Industry Daily

March 14, 2013 | Vol. 12 No. 52

OGD Director Greg Geba Resigns, Citing Differences in Vision

Office of Generic Drugs (OGD) Director Greg Geba is resigning, effective Friday — less than a year after taking charge.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Rejects Endo’s Petition to Deny Generics of Opana ER FDA Sets Fiscal 2014 GDUFA Self-Identification Deadline Generic Access Now: BPC Report Calls for Closure of ‘REMS Loophole’State AGs Push FDA to Require Abuse-Deterrent Opioid Generics

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.